Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
NCT ID | NCT05163080 |
Title | SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma (SURVIVE) (SURVIVE) |
Acronym | SURVIVE |
Recruitment | Active, not recruiting |
Gender | both |
Phase | Phase II |
Variant Requirements | No |
Sponsors | MimiVax, LLC |
Indications | |
Therapies | |
Age Groups: | senior | adult |
Covered Countries | USA |
Facility | Status | City | State | Zip | Country | Details |
---|---|---|---|---|---|---|
University of California | San Francisco | California | 94143 | United States | Details | |
Miami Cancer Institute | Miami | Florida | 33176 | United States | Details | |
Norton Cancer Center | Louisville | Kentucky | 40241 | United States | Details | |
Dana Farber Cancer Institute | Boston | Massachusetts | 02215 | United States | Details | |
Atlantic Health | Summit | New Jersey | 07960 | United States | Details | |
Roswell Park Comprehensive Cancer Center | Buffalo | New York | 14263 | United States | Details | |
NYU Langone Health | New York | New York | 10016 | United States | Details | |
Northwell | New York | New York | 10075 | United States | Details | |
Cleveland Clinic | Cleveland | Ohio | 44195 | United States | Details | |
Texas Oncology | Austin | Texas | 78705 | United States | Details | |
Fred Hutchinson Cancer Center (FHCC) | Seattle | Washington | 98109 | United States | Details |